# ZUMA-23 (NCT05605899)

> Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05605899
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Kite, A Gilead Company
- Conditions: High-risk Large B-cell Lymphoma (LBCL)
- Interventions: Axicabtagene Ciloleucel; Cyclophosphamide; Fludarabine; Etoposide; Rituximab; Doxorubicin; Vincristine; Prednisone
- Enrollment: 300
- Primary outcome: Event-free Survival (EFS) by Blinded Central Assessment

## Commentary we found

- YouTube: 32
- Podcasts: 20
- X threads: 11

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=zuma-23-nct05605899

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05605899", "email": "<work email>"}; the inbox owner confirms by the emailed link.